Clinical Trials at Hematology Oncology Consultants-Clarkston
As of August 2026, 33 paid clinical trials are recruiting at Hematology Oncology Consultants-Clarkston, located at Michigan Hematology Oncology, 5680 Bow Pointe Dr #201, Village of Clarkston, MI 48346, phone (248) 620-9600 in Clarkston, Michigan. Active studies at this site cover conditions such as Stage IVB Prostate Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
33 clinical trials at Hematology Oncology Consultants-Clarkston
·Clear filters·Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Family Communications After Genetic Testing
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Common conditions studied in Clarkston
- Stage IVB Prostate Cancer AJCC v8 (3 active studies)
- Anatomic Stage I Breast Cancer AJCC v8 (2 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (2 active studies)
- Chronic Lymphocytic Leukemia (2 active studies)
- HER2-negative Breast Cancer (2 active studies)
- Head and Neck Squamous Cell Carcinoma (2 active studies)
Leading research sponsors in Clarkston
- SWOG Cancer Research Network
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Barbara Ann Karmanos Cancer Institute
- NRG Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Clarkston?
There are approximately 53 recruiting clinical trials in Clarkston, Michigan listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Clarkston pay participants?
Most recruiting trials in Clarkston compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Clarkston?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Clarkston?
The most common conditions under active study in Clarkston include Stage IVB Prostate Cancer AJCC v8 (3), Anatomic Stage I Breast Cancer AJCC v8 (2), Anatomic Stage II Breast Cancer AJCC v8 (2), Chronic Lymphocytic Leukemia (2), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Clarkston?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Clarkston on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Clarkston?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Clarkston?
Recruiting research sites in Clarkston include Hematology Oncology Consultants-Clarkston, McLaren Cancer Institute-Clarkston, Newland Medical Associates-Clarkston, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Clarkston right now?
The largest active categories in Clarkston are Cancer & tumors (37), Cardiovascular (1). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Hematology Oncology Consultants-Clarkston?
Hematology Oncology Consultants-Clarkston is located at Michigan Hematology Oncology, 5680 Bow Pointe Dr #201, Village of Clarkston, MI 48346. Use the Google Maps link in the intro above to get directions.
How do I contact Hematology Oncology Consultants-Clarkston?
You can reach Hematology Oncology Consultants-Clarkston by phone at (248) 620-9600. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.